Roxadustat Treatment After PCI Among Patients With ST-Segment Elevation Myocardial Infarction

In this randomized clinical trial of patients with STEMI, roxadustat administration after PCI did not significantly reduce infarct size at 30 days compared with control. Secondary ventricular remodeling findings were exploratory and require confirmation.

Corresponding Authors: Xiaoxiang Yan, MD, PhD (cardexyanxx@hotmail.com), and Ruiyan Zhang, MD, PhD (zhangruiyan@263.net), Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Rd, Shanghai 200025, PR China.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.